Redfund Capital Corp (CSE:COPR, OTC:PNNRF, Frankfurt:O3X4) announced today that it is adding a new client to its budding client list: Biolog Inc.
Biolog has developed a patented system to infuse food and beverages with cannabis, which provides enhanced bioavailability — the amount of a substance that becomes available — and reduced onset times.
“Redfund Capital is specifically focused on funding cannabis-related companies that have strong growth potential and that is exactly what we see in Biolog,” said chief executive officer Meris Kott.
“Biolog’s products were specifically designed to solve the inconsistencies within the edible cannabis market and we are pleased to welcome them to the Redfund portfolio of companies.”
“The financing from Redfund will allow us to accelerate our product schedule. The patented process we deploy allows us to produce products that normal consumers or professional processors can utilize to turn virtually any food into a cannabis edible that is accurately dosed with highly bioavailable cannabinoids," said Bruce Bauer, chief executive officer of Biolog.
"While we will enter the marketplace with a strong patent portfolio, our internally developed testing regime, which is based on some of the most advanced laboratory equipment in the market, will ensure that consumers and processors can use our products with confidence.”
Technology protected by patents
The Biolog technology is protected by multiple patents and trade secrets, including a patent portfolio licensed from Lexaria, enabling consumers and processors to precisely dose almost any food or beverage with either cannabidiol (CBD), tetrahydrocannabinol (THC) or any combination of these or other cannabinoids.
The company said CBD edibles manufactured with Biolog's technology could offer improvements in bioavailability of up to 500%, while also reducing onset times for psychoactive effects from tetrahydrocannabinol (THC) to as fast as 15 to 20 minutes.